- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Adrian Hernandez Highlights the Use of Real-World Evidence and Current Barriers
In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.
This page contains sponsored advertising.
In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.
Transcript
What are the barriers that prevent the use of real-world evidence in meaningful ways?
There are a few. One is cultural. Just getting used to the concept of taking advantage of data every day that is being generated as part of healthcare and, also, someone’s life journey. The second thing is actually around quality. So, how do we understand what it means? What does the quality of the data implicate in terms of the certainty or uncertainty about the results?
And, then, finally, how do we make sure that we’re actually getting the right answers? So, certainly, there are methodological issues in terms of observational studies. There are also methodological issues in terms of randomized trials. So, how do we get closer to the truth? And combining those 3 efforts is really important for real-world evidence.
How does the United States’ use of real-world evidence compare with how it is used in other countries?
In some ways, it’s very progressive in terms of people actually making decisions. In terms of health decisions. So, healthcare systems are doing this every day. In some cases, it’s being used to inform what regulators have to decide on in terms of either expanding an indication or actually a new indication.
In the other places, however, it’s being incorporated more in the health system, and actually how that actually influences what they do for population health management. So, certain countries are actually very focused in terms of how they’re going to improve the trajectory for health over a 3- or 5-year period. So, they recognize the need for that is actually incorporating real-world evidence to drive outcomes and better health.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Pediatric Alopecia Areata Risks and Disparities Vary by Race and Ethnicity
October 30th 2024Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Studies Highlight Heavy Burden on Caregivers of Patients With DMD
October 28th 2024Caregivers of both adults and children with Duchenne muscular dystrophy (DMD) face significant disruptions to their work productivity and personal lives, underscoring the need for better treatments and support systems.
Read More
